Celgene entered into a partnership to take on autoimmune diseases with two of New Jersey-based Nimbus Therapeutics’ preclinical therapeutics.

Aeolus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Fast Track designation to AEOL 10150 for the prevention of fatal respiratory failure among patients at risk for radiation pneumonitis following a radiological/nuclear incident sufficient to cause the Acute Radiation Syndrome.

Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.

Roche’s Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said.

Aradigm Corp.’s inhaled antibiotic for a rare, incurable disorder affecting the lungs failed a late-stage study, sending the company’s shares down in premarket trading.

German drugmaker Bayer said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.

The U.S. FDA gave fast-track review status to Novartis’ medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer.

Alkermes’ experimental anti-depression drug ALKS-5461 significantly reduced symptoms in major depressive disorder patients not helped by standard treatments.

Roche said its Ocrevus multiple sclerosis drug controlled the most common form of the disease better than a rival’s medicine and worked against another form of MS for which there is no approved treatment.

Roche Holding AG said on Monday the U.S. Food and Drug Administration has granted priority review for atezolizumab for treating people with a specific type of lung cancer.   The designation covers treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expresses the protein PD-L1 as determined by an […]